Saturday, February 16, 2019

FDA Approves TactiCath SE for Ablation Treatment


Longtime professor of medicine Dr. Sanjiv M. Narayan has held teaching roles at colleges throughout California, including UC San Diego. He is currently a faculty member at Stanford University and the director of the Stanford Arrhythmia Center. A committed cardiologist and researcher, Sanjiv Narayan, MD, PhD, is a leading authority in the diagnosis and treatment of atrial fibrillation.

In January 2018, the United States Food and Drug Administration gave approval for the use of a new type of ablation catheter for the treatment of atrial fibrillation. Developed by Abbott, the TactiCath Contact Force Ablation Catheter SE (Sensor Enabled) discourages the electrical stimulations that can scar heart tissue. 

Physicians who have tried the catheter have praised it as a major advance in ablation therapy. Srijoy Mahapatra, MD, of Abbott says the TactiCath SE is the latest innovation in the company’s mission to advance ablation therapy by making it safer and easier to perform.